EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodelingAlyse M. DeHaan(University of Michigan), Kathleen M. Woods Ignatoski(Michigan Medicine)The ProstateJanuary 13, 200910.1002/pros.20903Cited by 45SaveCiteExport RISWatch citationsRelated PaperserbB-2 Overexpression in Human Mammary Epithelial Cells Confers Growth Factor Independence*|Endocrinology|1999|57